|Systematic (IUPAC) name|
|Mol. mass||355.860 g/mol|
|(what is this?)|
Batanopride (BMY-25,801) is an antiemetic drug of the benzamide class which acts as a selective 5-HT3 receptor antagonist. It was trialled to reduce nausea during cancer chemotherapy, but was never approved for medical use due to dose-limiting side effects including hypotension and long QT syndrome.
- Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. Journal of Pharmacology and Experimental Therapeutics. 1988 Mar;244(3):830-7. PMID 2978041
- Fleming GF, Vokes EE, McEvilly JM, Janisch L, Francher D, Smaldone L. Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. Cancer Chemotherapy and Pharmacology. 1991;28(3):226-7. PMID 1855280
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|